Phio Pharmaceuticals (PHIO) director Freeman received 10,000 shares
Stocks in this Quantisnow insightHealth Care
Insider transactions reported
Jonathan E Freeman (director at Phio Pharmaceuticals Corp., PHIO) reported that they received 10,000 shares on Feb 15, 2022. After these transactions the filing shows 20,364 shares held directly.
- Reporting person
- Freeman Jonathan E
| Date | Type | Security | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|
| Feb 15, 2022 | Grant or award (A) | Common stock, $0.0001 par value1, 2 | +10,000 | - | - | 20,364 direct |
Holdings before and after
- Common stock, $0.0001 par value: 10,364 to 20,364 direct
Footnotes from the filing
- 1. Represents shares underlying a restricted stock unit, which shares will vest in one installment on the first anniversary of the grant date.
- 2. Includes shares of common stock underlying unvested restricted stock units.
Transaction codes in this filing
- Grant or award:
- Code A marks a grant or award from the company under an exempt employee or director plan. Usually nothing is paid for it.
FAQ
What did Freeman report in this PHIO Form 4?
Jonathan E Freeman (director at Phio Pharmaceuticals Corp., PHIO) reported that they received 10,000 shares on Feb 15, 2022. After these transactions the filing shows 20,364 shares held directly.
How many PHIO shares does Freeman hold after this filing?
The filing shows 20,364 shares held directly after the reported transactions. Form 4 reports only the positions it lists, so this may not be every holding.
What does transaction code A mean on an SEC Form 4?
Code A marks a grant or award from the company under an exempt employee or director plan. Usually nothing is paid for it.
Historical context for PHIO
Earlier insider filings at PHIO
- Feb 17, 2022SEC Form 4: Ferrara Robert L was granted 10,000 shares, increasing direct ownership by 77% to 23,000 units
- Feb 17, 2022SEC Form 4: Dorman H. Paul was granted 10,000 shares, increasing direct ownership by 96% to 20,370 units
- Feb 17, 2022SEC Form 4: Dispersyn Gerrit was granted 126,000 shares, increasing direct ownership by 132% to 221,281 units
- Feb 17, 2022SEC Form 4: Cauwenbergh Geert was granted 10,000 shares, increasing direct ownership by 44% to 32,822 units
- Feb 17, 2022SEC Form 4: Bitterman Robert J was granted 10,000 shares, increasing direct ownership by 63% to 25,826 units
Quantisnow market dataNASDAQ
PHIO
Phio Pharmaceuticals Corp.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
Get push alerts for PHIO
Full PHIO profile on Quantisnow Follow PHIO and get a push notification the moment its next story breaks.
Original source Picked up and delivered by Quantisnow in real time